lifestyle.pluralist.com

Author: Quantum BioPharma

Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

April 2, 2026
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

April 1, 2026
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

March 30, 2026
Quantum Biopharma Provides Corporate Update

March 27, 2026
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

March 27, 2026
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

March 26, 2026
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

March 23, 2026
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

March 20, 2026
Quantum BioPharma Provides Corporate Update

March 11, 2026
Quantum BioPharma Provides Corporate Update

March 10, 2026